Back to top
more

Royalty Pharma (RPRX)

(Delayed Data from NSDQ)

$61.33 USD

61.33
2,357,557

+0.02 (0.03%)

Updated Aug 24, 2026 04:00 PM ET

After-Market: $61.32 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's What to Expect From Assurant's (AIZ) Q1 Earnings

by Zacks Equity Research

Assurant's (AIZ) first-quarter performance is likely to have benefited from higher yields in fixed maturity securities, lender-placed average insured values and organic growth across all products.

Zacks Equity Research

Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Zacks Equity Research

Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

RPRX or BX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

RPRX vs. BX: Which Stock Is the Better Value Option?

Zacks Equity Research

TEVA, Royalty Pharma Sign Funding Deal for Schizophrenia Drug

by Zacks Equity Research

Per the deal, Royalty Pharma is set to provide TEVA R&D funding support of up to $125 million to develop olanzapine LAI for treating schizophrenia.

Zacks Equity Research

Ryan Specialty Group (RYAN) Meets Q3 Earnings Estimates

by Zacks Equity Research

Ryan Specialty (RYAN) delivered earnings and revenue surprises of 0% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Houlihan Lokey (HLI) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Houlihan Lokey (HLI) delivered earnings and revenue surprises of 11% and 4.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?